Evofem Biosciences, Inc.

OTCPK:EVFM Stock Report

Market Cap: US$1.2m

Evofem Biosciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Saundra Pelletier

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage49.23%
CEO tenure8yrs
CEO ownership0.001%
Management average tenure2.4yrs
Board average tenure8yrs

Recent management updates

Recent updates

Evofem partners with a360 Media to support Phexxi prescription growth

Jul 21

Evofem announces peer-reviewed publication on birth control method

Jul 12

Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier

Jul 06

Evofem announces U.S. patent win for birth control method

Jun 30

Evofem: ACA Coverage Of Phexxi Is A Game Changer

Jan 18

CEO Compensation Analysis

How has Saundra Pelletier's remuneration changed compared to Evofem Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$6m

Jun 30 2025n/an/a

-US$6m

Mar 31 2025n/an/a

-US$3m

Dec 31 2024US$1mUS$580k

-US$9m

Sep 30 2024n/an/a

-US$11m

Jun 30 2024n/an/a

US$57m

Mar 31 2024n/an/a

US$47m

Dec 31 2023US$2mUS$560k

US$50m

Sep 30 2023n/an/a

US$44m

Jun 30 2023n/an/a

US$67m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$1mUS$812k

-US$78m

Sep 30 2022n/an/a

-US$119m

Jun 30 2022n/an/a

-US$283m

Mar 31 2022n/an/a

-US$192m

Dec 31 2021US$3mUS$812k

-US$206m

Sep 30 2021n/an/a

-US$194m

Jun 30 2021n/an/a

-US$150m

Mar 31 2021n/an/a

-US$169m

Dec 31 2020US$4mUS$781k

-US$142m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$3mUS$847k

-US$80m

Compensation vs Market: Saundra's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD586.75K).

Compensation vs Earnings: Saundra's compensation has been consistent with company performance over the past year.

CEO

Saundra Pelletier (55 yo)

8yrs
Tenure
US$1,177,838
Compensation

Ms. Saundra Pelletier is Non-Executive Director of IMAC Holdings, Inc. from June 2, 2025. She served as Director of Aditxt, Inc. since June 5, 2025 until September 23, 2025. She has served as Chief Executi...

Leadership Team

NamePositionTenureCompensationOwnership
Saundra Pelletier
Interim Chair8yrsUS$1.18m0.0012%
$ 14.2
Ivy Zhang
CFO & Secretary2.8yrsUS$695.26kno data
Ellen Thomas
Chief of Staffno datano datano data
Amy Raskopf
Chief Business Development Officer1yrno datano data
Kathy Gallo-Doyle
Senior Vice President of Commercial Operations2yrsno datano data
2.4yrs
Average Tenure

Experienced Management: EVFM's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Saundra Pelletier
Interim Chair8yrsUS$1.18m0.0012%
$ 14.2
Colin Rutherford
Independent Director8yrsUS$70.00k0%
$ 0
Lisa Rarick
Independent Director5.9yrsUS$55.00k0%
$ 0
Kim Kamdar
Independent Director8yrsUS$78.75k0%
$ 0
Tony O'Brien
Independent Lead Director8yrsUS$75.00k0%
$ 0
8.0yrs
Average Tenure
62yo
Average Age

Experienced Board: EVFM's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/04 02:40
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evofem Biosciences, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John TannerCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
I-Eh JenLaidlaw & Company (UK) Ltd